BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37550179)

  • 41. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
    Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
    Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma.
    Shao Y; Xiong S; Sun G; Dou W; Hu X; Yang W; Lia T; Deng S; Wei Q; Zeng H; Li X
    Cancer Med; 2020 Feb; 9(3):959-970. PubMed ID: 31840431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population-based evaluation of the risk factors and prognosis among renal cell carcinoma patients with initially diagnosed lung metastases.
    Zhang Z; Liang C; Hou B; Zhou L
    Actas Urol Esp (Engl Ed); 2021 Sep; 45(7):498-506. PubMed ID: 34332926
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of extensive necrosis in renal cell carcinoma.
    Collins J; Epstein JI
    Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
    Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
    [No Abstract]   [Full Text] [Related]  

  • 46. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.
    Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM
    Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chromophobe renal cell carcinoma with sarcomatoid change. A case report.
    Nagashima Y; Okudela K; Osawa A; Nakamura N; Kawasaki C; Moriyama M; Nakamura N; Nakatani Y; Kitamura H; Aoki I
    Pathol Res Pract; 2000; 196(9):647-51; discussion 652. PubMed ID: 10997740
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significance of TNM staging, Demographic and Histologic Features in Predicting the Prognosis of Renal Cell Carcinoma.
    Kucuk U; Pala EE; Sezer O; Cakir E; Bayol U; Divrik RT
    Acta Chir Belg; 2015; 115(3):202-7. PubMed ID: 26158251
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathologica Epidemiological Characteristics and Change Tendencies of Renal Cell Carcinoma in Shanxi Province of China from 2005 to 2014.
    Bai T; Wang L; Wang D; Yuan X; Bai W; Yang Q; Yang X
    PLoS One; 2015; 10(12):e0144246. PubMed ID: 26633179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503.
    Jay R; McKay RR; Werner L; Atkins MB; Van Allen EM; Olivier KM; Song J; Signoretti S; McDermott DF; Choueiri TK
    Urol Oncol; 2017 Mar; 35(3):117-118. PubMed ID: 28159495
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
    Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
    Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adult renal cell carcinoma with rhabdoid differentiation: incidence and clinicopathologic features in Chinese patients.
    Yang X; Xi C; Jin J; Zhou L; Su J; Liu L; Liu Y
    Ann Diagn Pathol; 2015 Apr; 19(2):57-63. PubMed ID: 25708024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.
    Saad AM; Gad MM; Al-Husseini MJ; Ruhban IA; Sonbol MB; Ho TH
    Clin Genitourin Cancer; 2019 Feb; 17(1):46-57.e5. PubMed ID: 30391138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database.
    Wei H; Miao J; Cui J; Zheng W; Chen X; Zhang Q; Liu F; Mao Z; Qiu S; Zhang D
    Sci Rep; 2021 Sep; 11(1):17822. PubMed ID: 34497343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnosis of Sarcomatoid Renal Cell Carcinoma With CT: Evaluation by Qualitative Imaging Features and Texture Analysis.
    Schieda N; Thornhill RE; Al-Subhi M; McInnes MD; Shabana WM; van der Pol CB; Flood TA
    AJR Am J Roentgenol; 2015 May; 204(5):1013-23. PubMed ID: 25905936
    [TBL] [Abstract][Full Text] [Related]  

  • 56. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
    Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma.
    Zheng W; Zhu W; Yu S; Li K; Ding Y; Wu Q; Tang Q; Zhao Q; Lu C; Guo C
    BMC Cancer; 2020 Nov; 20(1):1066. PubMed ID: 33148204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database-based Study.
    Pecoraro A; Palumbo C; Knipper S; Mistretta FA; Rosiello G; Tian Z; St-Hilaire PA; Shariat SF; Saad F; Lavallée L; Briganti A; Kapoor A; Fiori C; Porpiglia F; Karakiewicz PI
    Eur Urol Focus; 2021 Jul; 7(4):818-826. PubMed ID: 32169361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metastatic renal cell carcinoma to the urinary bladder: a report of 11 cases.
    Zhang M; Wah C; Epstein JI
    Am J Surg Pathol; 2014 Nov; 38(11):1516-21. PubMed ID: 25140895
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.
    Xu W; Anwaier A; Liu W; Wei G; Su J; Tian X; Xia J; Qu Y; Zhao J; Zhang H; Ye D
    Front Immunol; 2022; 13():953721. PubMed ID: 35979371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.